Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure
Open Access
- 8 March 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 119 (8) , 1690-1705
Abstract
Aims: The importance of autoantibodies (AABs) against adrenergic/muscarinic receptors in heart failure (HF) is not well-understood. We investigated the prevalence and clinical/prognostic associations of four AABs recognizing the M2-muscarinic receptor or the β1-, β2-, or β3-adrenergic receptor in a large and well-characterized cohort of patients with HF. Methods and results: Serum samples from 2256 patients with HF from the BIOSTAT-CHF cohort and 299 healthy controls were analysed using newly established chemiluminescence immunoassays. The primary outcome was a composite of all-cause mortality and HF rehospitalization at 2-year follow-up, and each outcome was also separately investigated. Collectively, 382 (16.9%) patients and 37 (12.4%) controls were seropositive for ≥1 AAB (P = 0.045). Seropositivity occurred more frequently only for anti-M2 AABs (P = 0.025). Amongst patients with HF, seropositivity was associated with the presence of comorbidities (renal disease, chronic obstructive pulmonary disease, stroke, and atrial fibrillation) and with medication use. Only anti-β1 AAB seropositivity was associated with the primary outcome [hazard ratio (95% confidence interval): 1.37 (1.04–1.81), P = 0.024] and HF rehospitalization [1.57 (1.13–2.19), P = 0.010] in univariable analyses but remained associated only with HF rehospitalization after multivariable adjustment for the BIOSTAT-CHF risk model [1.47 (1.05–2.07), P = 0.030]. Principal component analyses showed considerable overlap in B-lymphocyte activity between seropositive and seronegative patients, based on 31 circulating biomarkers related to B-lymphocyte function. Conclusions: AAB seropositivity was not strongly associated with adverse outcomes in HF and was mostly related to the presence of comorbidities and medication use. Only anti-β1 AABs were independently associated with HF rehospitalization. The exact clinical value of AABs remains to be elucidated.Keywords
Funding Information
- European Commission (FP7-242209-BIOSTAT-CHF; EudraCT 2010-020808-29)
- German Federal Ministry for Economic Affairs and Energy
- European Social Fund Plus
This publication has 38 references indexed in Scilit:
- Autoantibodies against the β3-Adrenoceptor Protect from Cardiac Dysfunction in a Rat Model of Pressure OverloadPLOS ONE, 2013
- T cell–independent B cell activation induces immunosuppressive sialylated IgG antibodiesJournal of Clinical Investigation, 2013
- Natural autoantibodies and associated B cells in immunity and autoimmunityAutoimmunity, 2013
- β1-Adrenoceptor Autoantibodies from DCM Patients Enhance the Proliferation of T Lymphocytes through the β1-AR/cAMP/PKA and p38 MAPK PathwaysPLOS ONE, 2012
- Drug‐like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart functionBritish Journal of Pharmacology, 2012
- Molecular Mimicry as a Mechanism of Autoimmune DiseaseClinical Reviews in Allergy & Immunology, 2011
- Recombination centres and the orchestration of V(D)J recombinationNature Reviews Immunology, 2011
- B-cell tolerance: mechanisms and implicationsCurrent Opinion in Immunology, 2010
- Definition of human autoimmunity — autoantibodies versus autoimmune diseaseAutoimmunity Reviews, 2010
- Regulation of plasma-cell developmentNature Reviews Immunology, 2005